Complete enrollment for the higher-dose cohort
Not delivered by the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 17 Dec 2021
- Due
- 30 Jun 2022
- Checked
- 1 Oct 2026
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“higher-dose cohort enrollment expected to be completed by mid-2022”
What we found
Evidence strength A What the grades mean
The company failed to complete enrollment for the higher-dose cohort by mid-2022, subsequently pushing the completion target to the first half of 2023.
-
A uniQure N.V. 10-Q filed 2022-11-02
“We plan to resume patient dosing in the open-label European study in the fourth quarter of 2022 and complete enrollment of the remaining five of the nine patient higher-dose cohort in the first half of 2023.” ✓ confirmed on the page
Market reaction: the shares moved +4.2% against the S&P 500 over the three sessions around the disclosure (1 Nov 2022 to 4 Nov 2022). What this measures
Checked 1 Oct 2026.
Commitment lineage
Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.
- Deadline drift +365 days
- 2 versions
-
Version 1 · original · stated 17 Dec 2021
Deadline 30 Jun 2022 (“mid-2022”) · wording expected
-
Version 2 · stated 9 May 2023
Deadline 30 Jun 2023 (“mid- 2023”) · wording expected
“Patient enrollment in the higher-dose cohort is expected to complete in mid- 2023”
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Complete
- Deliverable
- higher-dose cohort enrollment
- Where
- United States
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- High
- Depends on
- Customer, Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: disagreesClaude (Anthropic) re-read the evidence blind and read it as “Late”.
- Tie-breakA stronger model read the evidence and both earlier answers, without knowing which was recorded, and agrees with the recorded outcome.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you uniQure N.V.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-QURE-001786 · Corrections policy